[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580773":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":39,"slug":25,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":25,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":60,"whyStopped":25,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":25},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (Treatment)","EXPERIMENTAL","50 patients will recieve Atomoxetine, 0.5-1.2 mg\u002Fkg\u002Fday, administered in the evening for six months.\n\nFrequency of nocturnal enuresis episodes, recorded by parents in a nightly log. ADHD symptoms, assessed using Conners-48 scores at baseline, 1, 3, and 6 months.",[13],"Drug: Atomoxetine",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 (Control)","50 participants will receive Placebo identical in form and dosing schedule. for 6 months.\n\nFrequency of nocturnal enuresis episodes, recorded by parents in a nightly log. ADHD symptoms, assessed using Conners-48 scores at baseline, 1, 3, and 6 months.",[18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Atomoxetine","Atomoxetine, 0.5-1.2 mg\u002Fkg\u002Fday, administered in the evening for six months.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo identical in form and dosing schedule for six months.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Osama Ibrahim Younes","CONTACT","01024188789","osamaebrahim2012@gmail.com",{"type":37,"investigatorFullName":32,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","lecturer of psychiatry","100580773",false,"NCT06841666","Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study","Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD","Inclusion Criteria:\n\n* Children aged 6-12 years diagnosed with ADHD per Conners-48 scale. Children experiencing primary nocturnal enuresis.\n\nExclusion Criteria:\n\n* Secondary causes of enuresis (e.g., urinary tract infections, diabetes). Use of other enuresis treatments. Known contraindications to atomoxetine.",true,"ALL","6 Years","12 Years",{"count":50,"type":51},100,"ESTIMATED","INTERVENTIONAL",[54],"EARLY_PHASE1","1. Primary Aim: To evaluate the efficacy of atomoxetine in reducing the frequency of primary nocturnal enuresis episodes in children with ADHD.\n2. Secondary Aim: To determine if improvements in attention symptoms correlate with reductions in nocturnal enuresis episodes.",[57,58],"ADHD","Primary Nocturnal Enuresis",[58,57,22],"NOT_YET_RECRUITING","2025-02-25",{"date":63,"type":64},"2025-02-27","ACTUAL",{"date":66,"type":51},"2025-02-28",{"date":68,"type":51},"2025-09-05",{"name":5,"class":6}]